RVL Pharmaceuticals plc
RVLPNASDAQHealthcare
$0.03
$-0.01(-32.05%)
Market Cap$3141649
P/E Ratio—
52W High$1.66
52W Low$0.0026
RVL Pharmaceuticals plc (RVLP) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · RVLP · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $49.72M | $17.50M | $27.76M | $240.03M | $263.70M |
| Cost of Revenue | $9.46M | $3.62M | $3.29M | $111.63M | $140.08M |
| Gross Profit | $40.27M | $13.88M | $24.47M | $128.40M | $123.62M |
| Gross Margin %(computed) | 80.98% | 79.33% | 88.14% | 53.49% | 46.88% |
| Operating Expenses | |||||
| R&D Expenses | $3.97M | $6.93M | $13.39M | $32.32M | $43.69M |
| G&A Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Total Operating Expenses | $85.94M | $94.39M | $86.21M | $125.35M | $117.94M |
| Operating Income | ($45.68M) | ($80.51M) | ($61.74M) | $3.94M | ($98.54M) |
| Operating Margin %(computed) | -91.87% | -460.03% | -222.40% | 1.64% | -37.37% |
| Interest Income | $2.86M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $3.11M | $4.02M | $4.09M | $18.21M | $20.79M |
| Income Before Tax | ($51.71M) | ($82.53M) | ($94.80M) | ($298.02M) | ($118.66M) |
| Income Tax Expense | ($0.02M) | $0.32M | ($5.78M) | ($27.12M) | ($8.98M) |
| Net Income | ($51.69M) | ($82.85M) | ($89.01M) | ($270.90M) | ($109.68M) |
| Net Margin %(computed) | -103.96% | -473.40% | -320.63% | -112.86% | -41.59% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.58 | $-1.23 | $-1.47 | $-5.17 | $-2.42 |
| Wtd Avg Shares | 89.80M | 67.35M | 60.65M | 52.37M | 45.28M |
| EBITDA | ($36.19M) | ($73.67M) | ($69.72M) | ($49.80M) | ($664.39M) |
| EBITDA Margin %(computed) | -72.78% | -420.94% | -251.14% | -20.75% | -251.95% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more RVL Pharmaceuticals plc data
About RVL Pharmaceuticals plc (RVLP) Income Statement
RVL Pharmaceuticals plc (RVLP) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, RVLP reported revenue of $0.05B, gross profit of $0.04B (gross margin 80.98%), and net income of ($0.05B) — a net profit margin of -103.96%.
Frequently asked questions
RVLP · 4 questionsRVL Pharmaceuticals plc (RVLP) reported revenue of $0.05B for 2022, up 184.1% year-over-year.
RVLP revenueRVLP salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09